Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 7/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154149 | 0.89 | CYP3A4 (0.39) | SPRCRACR2A | |
| SCHEMBL20139176 | 0.87 | TLR9 (0.38) | SPRHIF1A | |
| SCHEMBL20138918 | 0.87 | KDM4E (0.44) | — | |
| SCHEMBL23356510 | 0.86 | HCRTR1 (0.30) | — | |
| SCHEMBL20139171 | 0.86 | TLR9 (0.41) | SPR | |
| SCHEMBL23369034 | 0.84 | TLR8 (0.31) | — | |
| SCHEMBL20154104 | 0.84 | SPR (0.34) | SPR | |
| SCHEMBL20154107 | 0.84 | CHRNA4 (0.38) | L3MBTL1 | |
| SCHEMBL20138948 | 0.84 | SPR (0.36) | SPR | |
| SCHEMBL20154105 | 0.84 | SLC9A1 (0.39) | SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | claimed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | SPR 1666/4885L3MBTL1 2800/4885HIF1A 3280/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | SPR 1666/4885L3MBTL1 2800/4885HIF1A 3280/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | SPR 1666/4885L3MBTL1 2800/4885HIF1A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.